amifampridine has been researched along with Autosomal Dominant Cerebellar Ataxia, Type II in 1 studies
Amifampridine: 4-Aminopyridine derivative that acts as a POTASSIUM CHANNEL blocker to increase release of ACETYLCHOLINE from nerve terminals. It is used in the treatment of CONGENITAL MYASTHENIC SYNDROMES.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tsunemi, T | 1 |
| Ishikawa, K | 1 |
| Tsukui, K | 1 |
| Sumi, T | 1 |
| Kitamura, K | 1 |
| Mizusawa, H | 1 |
1 other study available for amifampridine and Autosomal Dominant Cerebellar Ataxia, Type II
| Article | Year |
|---|---|
The effect of 3,4-diaminopyridine on the patients with hereditary pure cerebellar ataxia.
Topics: 4-Aminopyridine; Amifampridine; Ataxia; Drug Administration Schedule; Female; Genetic Predisposition | 2010 |